Fluorescent Intra-operative Tumor Margin Examination

Sarcoma Clinical Trial

— ICGTM  

Official title:

Evaluation of Intraoperative Tumor Margin Identification With Fluorescent Dye Imaging

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04719156
• Other study ID #: STUDY19110051
• Status: Recruiting
• Phase: Phase 2
• Start date: March 2, 2021
• Est. completion date: June 2025

Study information

• Verified date: February 2024
• Source: University of Pittsburgh
• Contact: Beata Krawczyk, krawbx@upmc.edu
• Phone: 412-401-3000
• Email: krawbx[@]upmc.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Tumor margin confirmation is important to confirming appropriate disease excision. Current standard of care is to take select margin samples to pathology for intra-operative readings. However, this is expensive, time consuming, and only assesses the margin contained within the specific sample. In prior work the investigators have determined that indocyanine green (ICG) is highly specific to the tumor bed when injected shortly before surgery. The investigators hypothesize that ICG will be able to accurately identify residual positive tumor margins during sarcoma excision procedures.

Description:

Experimental Design:

1. A physician investigator will obtain consent during the pre-operative appointment. Study team members may assist with the discussion.

2. Upon arrival to the pre-operative area 2 hours prior to surgery, the participant will be injected with 2.0 mg/kg ICG (Indocyanine Green Dye) as per standard protocol: during regular pre-operative work-up, during which a standard of care IV is inserted. The PI or resident physician will administer the injection.

3. The participant will undergo the tumor removal surgery as planned pre-operatively.

To assess the accuracy and precision of ICG dye localization within tumor, not non-tumor, a small sample of tumor and a small sample of native tissue will be obtained for microscopy analysis (ICG fluorescence is possible on slides following frozen sectioning) 30 seconds, no intra-operative delay.

4. Once the tumor is removed to the satisfaction of the surgeon, ICG Angiography (SPY PHI) will be performed to detect any residual signal, 2-3 minutes, no re-draping required.

The surgeon will complete a "feedback sheet" that assesses if the tumor was completely excised (or an intentional positive margin was left).

5. The operative surgeon will be blinded to the angiography result. ICG Angiography will be performed by the resident or surgical staff, without surgeon involvement. No study team members are blinded.

6. The dose that will be administered 2.0 mg/Kg IC. Doses are being based on measurements on post-washout signal (or the remaining signal after the dye is metabolized). Weight based dosing is therefore far more important. The proposed dosing is not close to the LD50 (median lethal dose) of ICG and no side effects are anticipated with the increased dose.

7. The Stryker team will be perform an in-service for SPY PHI ( SPY portable hand held imaging device) for all OR staff members, and individual demonstrations for each service resident will be performed. The device is very simple to use and no active measurements need to be made. No extended anesthesia will be required.

8. The participant will be monitored for recurrence, which will be compared with ICG angiography findings intra-operatively.

9. Study efficacy will be evaluated every 6 months, as early-termination and clinical translation will be indicated should accuracy be proven in compliance with IRB (Institutional Review Board) "do no harm" rules.

10. Radiographs, that are completed post operatively during the standard of care visit, will be reviewed for this research.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 110
• Est. completion date: June 2025
• Est. primary completion date: December 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 100 Years

Eligibility

Inclusion Criteria:

• Patients above the age of 18 with a primary musculoskeletal tumor that has been indicated for surgical excision by a fellowship trained orthopaedic oncologist.

• Surgical consent was obtained prior to research consent.

• Patients with a biopsy-confirmed primary soft tissue or bone tumor that has not been previously excised and has a known risk of local or remote recurrence.

Exclusion Criteria:

• Patients below the age of 18

• Pregnancy, breast feeding

• Patients with a history of anaphylactic reaction to contrast media or fluorescein allergy

• Prior surgery local to the mass being excised

• Non- or minimally-recurrent masses (i.e. osteochondroma)

• Dialysis, renal failure, uremia

Related Conditions & MeSH terms

• Sarcoma

Intervention

Drug:
• Indocyanine green solution administered at 2.0mg/kg.
Dosing of ICG to be administered at 2.0mg/kg, two hours prior to surgery.

Device:
• Stryker SPY-PHI Imaging Device
The SPY-PHI system is used with the ICG dye to provide fluorescence images.

Locations

Country	Name	City	State
United States	Alma E Heyl	Pittsburgh	Pennsylvania

Sponsors (2)

Lead Sponsor	Collaborator
Kurt Weiss	Stryker Nordic

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Tumor recurrence as predicted by the surgeon vs. identified with SPY.	The proportion of tumors declared "completely removed" by the surgeon that recur locally will be compared those with SPY-identified residual disease.	During surgery for tumor removal
Secondary	Comparison of ICG angiography with pathologic evaluation	The ICG signal accessed at the time of surgery, will be compared with final anatomic pathology in order to discern its degree of accuracy.	Over a two year follow up period